The Center for Breakthrough Medicines (CBM), a CDMO founded in 2019, is getting financial backing from South Korean financial group SK Inc. to expand its manufacturing capacity.
The two companies didn’t disclose a dollar amount, but CBM said it will use the funding to build out its manufacturing suite as well as support operations, research and lab capabilities.
When the expansion is complete, CBM will occupy about 700,000 square feet at the Discovery Labs that are part of what is known as Cellicon Valley in King of Prussia, Pennsylvania, a former GlaxoSmithKline site.
